The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Long-term survival with glioblastoma multiforme
Abstract
The median survival of glioblastoma patients is approximately 12 months. However, 3-5% of the patients survives for more than 3 years and are referred to as long-term survivors. The clinical and molecular factors that contribute to long-term survival are still unknown. To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre. An evaluation form was developed and used to document demographic, clinical and treatment-associated parameters. In addition, environmental risk factors, associated diseases and occupational risks were assessed. These patients were characterized by young age at diagnosis and a good initial Karnofsky performance score (KPS). None of the evaluated socioeconomic, environmental and occupational factors were associated with long-term survival. Molecular analyses revealed MGMT hypermethylation in 28 of 36 tumours (74%) investigated. TP53 mutations were found in 9 of 31 tumours (29%) and EGFR amplification in 10 of 38 tumours (26%). Only 2 of 32 tumours (6%) carried combined 1p and 19q deletions. Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group. Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationStummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“Recent data have confirmed that the extent of resection is associated with improved progression-free survival (Stummer et al., 2006).”
BackgroundInactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
The Molecular Basis of Turcot's Syndrome
Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., Krush, A. J., Berk, T., Cohen, Z., Tetu, B., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321302 · Cited by 1,133
Fine, H. A., Dear, K. B. G., Loeffler, J. S., Mc Black, P. L., & Canellos, G. P. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s · Cited by 864
Cited by
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
A survey of MRI-based medical image analysis for brain tumor studies
Bauer, S., Wiest, R., Nolte, L.-P., & Reyes, M. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/13/r97 · Cited by 1,036
Wick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Self-citationMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationGlioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Self-citationMatrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Survival in glioblastoma: a review on the impact of treatment modalities
Delgado-López, P. D., & Corrales-García, E. M. (2016) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1497-x · Cited by 659
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Self-citationGlioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Epidemiology and Outcome of Glioblastoma
Department of Neurosurgery, J. U. H. A. M. S., TAMIMI, A. F., JUWEID, M., & Department of Radiology and Nuclear Medicine, J. U. H. A. M. S. (2017) · Glioblastoma · doi:10.15586/codon.glioblastoma.2017.ch8 · Cited by 484
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 471
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 456
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Goff, S. L., Morgan, R. A., Yang, J. C., Sherry, R. M., Robbins, P. F., Restifo, N. P., Feldman, S. A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000260 · Cited by 377
Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma
Yaghoubi, S. S., Jensen, M. C., Satyamurthy, N., Budhiraja, S., Paik, D., Czernin, J., & Gambhir, S. S. (2009) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1278 · Cited by 366
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Ten-year survival in glioblastoma. A systematic review
Tykocki, T., & Eltayeb, M. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.05.002 · Cited by 342
Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D., & Brennan, P. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-68011-4 · Cited by 305
Ni, D., Zhang, J., Bu, W., Xing, H., Han, F., Xiao, Q., Yao, Z., Chen, F., He, Q., Liu, J., et al. (2014) · ACS Nano · doi:10.1021/nn406197c · Cited by 300
Review Glioblastoma multiforme – an overview
Urbańska, K., Sokołowska, J., Szmidt, M., & Sysa, P. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.40559 · Cited by 276
Zuccoli, G., Marcello, N., Pisanello, A., Servadei, F., Vaccaro, S., Mukherjee, P., & Seyfried, T. N. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-33 · Cited by 267
Prasanna, P., Patel, J., Partovi, S., Madabhushi, A., & Tiwari, P. (2017) · European Radiology · doi:10.1007/s00330-016-4637-3 · Cited by 261
Segmentation of glioma tumors in brain using deep convolutional neural network
Hussain, S., Anwar, S. M., & Majid, M. (2018) · Neurocomputing · doi:10.1016/j.neucom.2017.12.032 · Cited by 257
Selective Targeting of Brain Tumors with Gold Nanoparticle-Induced Radiosensitization
Joh, D. Y., Sun, L., Stangl, M., Al Zaki, A., Murty, S., Santoiemma, P. P., Davis, J. J., Baumann, B. C., Alonso-Basanta, M., Bhang, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062425 · Cited by 252
Fan, C.-H., Ting, C.-Y., Lin, H.-J., Wang, C.-H., Liu, H.-L., Yen, T.-C., & Yeh, C.-K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.099 · Cited by 225
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Omoruyi, S. I., Ekpo, O. E., Semenya, D. M., Jardine, A., & Prince, S. (2020) · Apoptosis · doi:10.1007/s10495-020-01594-5 · Cited by 53
Rickert, C. H., Riemenschneider, M. J., Schachenmayr, W., Richter, H., Bockhorn, J., Reifenberger, G., & Paulus, W. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00199.x · Cited by 23
Self-citationJavanmard, A.-R., Jahanbakhshi, A., Nemati, H., Mowla, S. J., & Soltani, B. M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01311-7 · Cited by 9
Thanasupawat, T., Glogowska, A., Pascoe, C., Krishnan, S. N., Munir, M., Begum, F., Beiko, J., Krcek, J., Del Bigio, M. R., Pitz, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179566 · Cited by 8
Metadata
- Authors
- Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., Weller, M., Schackert, G., & for the German Glioma Network
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- 2596-2606
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2151794458
- Cited by
- 887
- References
- 70
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.